GlassScriptPhysician profile
Kenneth D Barofsky
NPI 1457465080
$5,261.29
in general payments reported to CMS, 2019-2025
30 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $657 · 2021: $91.88 · 2022: $475 · 2023: $392 · 2024: $763 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,428.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $687.45 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.92 | 2019-2020 | |
| Inspire Medical Systems, INC. | $275.27 | 2023-2025 | Inspire |
| United Therapeutics Corporation | $232.80 | 2024 | Tyvaso |
| Philips North America LLC | $222.51 | 2019-2023 | |
| Genentech USA, INC. | $185.71 | 2019-2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $184.91 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $180.90 | 2019-2020 | |
| Genzyme Corporation | $180.05 | 2019-2020 | |
| Pulmonx Corporation | $137.89 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abiomed | $133.45 | 2025 | |
| Grifols USA, LLC | $117.07 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $102.78 | 2019-2021 | |
| Harmony Biosciences LLC | $87.42 | 2022-2025 | Wakix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $74.74 | 2019-2020 | |
| Baxter Healthcare | $61.28 | 2023-2025 | Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $46.76 | 2019-2020 | |
| Vapotherm INC | $44.80 | 2019-2024 | Vapotherm |
| Amgen INC. | $44.00 | 2022-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $39.91 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $39.42 | 2019 | |
| Resmed Corp | $34.64 | 2019-2025 | |
| Electromed, INC. | $32.74 | 2019 | |
| Insmed, INC. | $30.41 | 2019-2022 | |
| Pfizer INC. | $29.60 | 2019 | |
| Apria Healthcare LLC | $17.73 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.84 | 2020 | |
| Circassia INC. | $14.34 | 2019 | |
| Merck Sharp & Dohme LLC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Barofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.